Stereotactic radiosurgery of acoustic tumors

P. S. Roland, Deborah Eston

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Stereotactic radiotherapy has an inherent disadvantage in that it does not directly reduce tumor volume. In this increasing environment of cost-containment, however, this modality offers several advantages (see box). Some investigators believe that, over the next generation, stereotactic radiotherapy will be the mainstay of vestibular schwannoma care, with micro-surgery being the exception and being reserved for patients needing urgent decompression and for very young patients [12]. Increasing numbers of patients are undergoing stereotactic radiotherapy as a matter of preference following the provision of sufficient information on the two treatment procedures. When counseling younger patients, it is important to remember that no long-term data about the control rate for stereotactic radiotherapy with the most recent, lower doses are available. Also, surgical salvage, which is necessary in some patients, produces a poor outcome following radiation therapy. Published reports have demonstrated similar facial nerve, hearing preservation, and tumor control rates in the short term only [32,33]. Data is insufficient to assess the risk for inducing a secondary, treatment-related malignancy. Until long-term results are available, stereotactic radiotherapy should be reserved for medically infirm patients, elderly patients, patients with contralateral deafness or bilateral tumors, and patients who have failed prior microsurgery. Radiotherapy is not the preferred primary treatment modality for vestibular schwannoma based on currently published results.

Original languageEnglish (US)
Pages (from-to)343-355
Number of pages13
JournalOtolaryngologic Clinics of North America
Volume35
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Acoustic Neuroma
Radiosurgery
Radiotherapy
Neoplasms
Microsurgery
Cost Control
Facial Nerve
Deafness
Decompression
Tumor Burden
Hearing
Counseling
Therapeutics
Research Personnel

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Stereotactic radiosurgery of acoustic tumors. / Roland, P. S.; Eston, Deborah.

In: Otolaryngologic Clinics of North America, Vol. 35, No. 2, 2002, p. 343-355.

Research output: Contribution to journalArticle

Roland, P. S. ; Eston, Deborah. / Stereotactic radiosurgery of acoustic tumors. In: Otolaryngologic Clinics of North America. 2002 ; Vol. 35, No. 2. pp. 343-355.
@article{95abf8b902bb4419a4146a228497fa04,
title = "Stereotactic radiosurgery of acoustic tumors",
abstract = "Stereotactic radiotherapy has an inherent disadvantage in that it does not directly reduce tumor volume. In this increasing environment of cost-containment, however, this modality offers several advantages (see box). Some investigators believe that, over the next generation, stereotactic radiotherapy will be the mainstay of vestibular schwannoma care, with micro-surgery being the exception and being reserved for patients needing urgent decompression and for very young patients [12]. Increasing numbers of patients are undergoing stereotactic radiotherapy as a matter of preference following the provision of sufficient information on the two treatment procedures. When counseling younger patients, it is important to remember that no long-term data about the control rate for stereotactic radiotherapy with the most recent, lower doses are available. Also, surgical salvage, which is necessary in some patients, produces a poor outcome following radiation therapy. Published reports have demonstrated similar facial nerve, hearing preservation, and tumor control rates in the short term only [32,33]. Data is insufficient to assess the risk for inducing a secondary, treatment-related malignancy. Until long-term results are available, stereotactic radiotherapy should be reserved for medically infirm patients, elderly patients, patients with contralateral deafness or bilateral tumors, and patients who have failed prior microsurgery. Radiotherapy is not the preferred primary treatment modality for vestibular schwannoma based on currently published results.",
author = "Roland, {P. S.} and Deborah Eston",
year = "2002",
doi = "10.1016/S0030-6665(02)00002-6",
language = "English (US)",
volume = "35",
pages = "343--355",
journal = "Otolaryngologic Clinics of North America",
issn = "0030-6665",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Stereotactic radiosurgery of acoustic tumors

AU - Roland, P. S.

AU - Eston, Deborah

PY - 2002

Y1 - 2002

N2 - Stereotactic radiotherapy has an inherent disadvantage in that it does not directly reduce tumor volume. In this increasing environment of cost-containment, however, this modality offers several advantages (see box). Some investigators believe that, over the next generation, stereotactic radiotherapy will be the mainstay of vestibular schwannoma care, with micro-surgery being the exception and being reserved for patients needing urgent decompression and for very young patients [12]. Increasing numbers of patients are undergoing stereotactic radiotherapy as a matter of preference following the provision of sufficient information on the two treatment procedures. When counseling younger patients, it is important to remember that no long-term data about the control rate for stereotactic radiotherapy with the most recent, lower doses are available. Also, surgical salvage, which is necessary in some patients, produces a poor outcome following radiation therapy. Published reports have demonstrated similar facial nerve, hearing preservation, and tumor control rates in the short term only [32,33]. Data is insufficient to assess the risk for inducing a secondary, treatment-related malignancy. Until long-term results are available, stereotactic radiotherapy should be reserved for medically infirm patients, elderly patients, patients with contralateral deafness or bilateral tumors, and patients who have failed prior microsurgery. Radiotherapy is not the preferred primary treatment modality for vestibular schwannoma based on currently published results.

AB - Stereotactic radiotherapy has an inherent disadvantage in that it does not directly reduce tumor volume. In this increasing environment of cost-containment, however, this modality offers several advantages (see box). Some investigators believe that, over the next generation, stereotactic radiotherapy will be the mainstay of vestibular schwannoma care, with micro-surgery being the exception and being reserved for patients needing urgent decompression and for very young patients [12]. Increasing numbers of patients are undergoing stereotactic radiotherapy as a matter of preference following the provision of sufficient information on the two treatment procedures. When counseling younger patients, it is important to remember that no long-term data about the control rate for stereotactic radiotherapy with the most recent, lower doses are available. Also, surgical salvage, which is necessary in some patients, produces a poor outcome following radiation therapy. Published reports have demonstrated similar facial nerve, hearing preservation, and tumor control rates in the short term only [32,33]. Data is insufficient to assess the risk for inducing a secondary, treatment-related malignancy. Until long-term results are available, stereotactic radiotherapy should be reserved for medically infirm patients, elderly patients, patients with contralateral deafness or bilateral tumors, and patients who have failed prior microsurgery. Radiotherapy is not the preferred primary treatment modality for vestibular schwannoma based on currently published results.

UR - http://www.scopus.com/inward/record.url?scp=0035992033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035992033&partnerID=8YFLogxK

U2 - 10.1016/S0030-6665(02)00002-6

DO - 10.1016/S0030-6665(02)00002-6

M3 - Article

C2 - 12391622

AN - SCOPUS:0035992033

VL - 35

SP - 343

EP - 355

JO - Otolaryngologic Clinics of North America

JF - Otolaryngologic Clinics of North America

SN - 0030-6665

IS - 2

ER -